Comprehensive characterization of the peroxisome proliferator activated receptor-δ agonist GW501516 for horse doping control analysis.
GW501516
LC-HRMS/MS
horse doping control
in vitro/in vivo metabolism
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
25
01
2021
received:
16
12
2020
accepted:
02
02
2021
pubmed:
7
2
2021
medline:
15
12
2021
entrez:
6
2
2021
Statut:
ppublish
Résumé
According to international sport institutions, the use of peroxisome proliferator activated receptor (PPAR)-δ agonists is forbidden at any time in athlete career due to their capabilities to increase physical and endurance performances. The (PPAR)-δ agonist GW501516 is prohibited for sale but is easily available on internet and can be used by cheaters. In the context of doping control, urine is the preferred matrix because of the non-invasive nature of sampling and providing broader exposure detection times to forbidden molecules but often not detected under its native form due to the organism's metabolism. Even if urinary metabolism of G501516 has been extensively studied in human subjects, knowledge on GW501516 metabolism in horses remains limited. To fight against doping practices in horses' races, GW501516 metabolism has to be studied in horse urine to identify and characterize the most relevant target metabolites to ensure an efficient doping control. In this article, in vitro and in vivo experiments have been conducted using horse S9 liver microsome fractions and horse oral administration route, respectively. These investigations determined that the detection of GW501516 must be performed in urine on its metabolites because the parent molecule was extremely metabolized. To maximize analytical method sensitivity, the extraction conditions have been optimized. In accordance with these results, a qualitative analytical method was validated to detect the abuse of GW501516 based on its most relevant metabolites in urine. This work enabled the Laboratoire des Courses Hippiques (LCH) to highlight two cases of illicit administration of this forbidden molecule in post-race samples.
Substances chimiques
GW 501516
0
PPAR delta
0
Thiazoles
0
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1191-1202Informations de copyright
© 2021 John Wiley & Sons, Ltd.
Références
Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J. 2014;13(1):17. https://doi.org/10.1186/1475-2891-13-17
Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta. 1996;1302(2):93-109. https://doi.org/10.1016/0005-2760(96)00066-5
Gupta RA, Wang D, Katkuri S, Wang H, Dey SK, DuBois RN. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-δ accelerates intestinal adenoma growth. Nat Med. 2004;10(3):245-247. https://doi.org/10.1038/nm993
Sahebkar A, Chew GT, Watts GF. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014;15(4):493-503. https://doi.org/10.1517/14656566.2014.876992
Thevis M, Geyer H, Thomas A, Schänzer W. Trafficking of drug candidates relevant for sports drug testing: detection of non-approved therapeutics categorized as anabolic and gene doping agents in products distributed via the internet. Drug Test Anal. 2011;3(5):331-336. https://doi.org/10.1002/dta.283
Chen W, Gao R, Xie X, et al. A metabolomic study of the PPARδ agonist GW501516 for enhancing running endurance in Kunming mice. Sci Rep. 2015;5(1):9884. https://doi.org/10.1038/srep09884
Guerrieri D, Moon HY, van Praag H. Exercise in a pill: the latest on exercise-Mimetics. Brain Plast. 2020;2(2):153-169. https://doi.org/10.3233/bpl-160043
Narkar VA, Downes M, Yu RT, et al. AMPK and PPARdelta agonists are exercise mimetics. Cell. 2008;134(3):405-415. https://doi.org/10.1016/j.cell.2008.06.051
Zizola C, Kennel PJ, Akashi H, et al. Activation of PPARδ signaling improves skeletal muscle oxidative metabolism and endurance function in an animal model of ischemic left ventricular dysfunction. Am J Physiol Heart Circ Physiol. 2015;308(9):H1078-H1085. https://doi.org/10.1152/ajpheart.00679.2014
IFHA. International agreement on breeding, racing and wagering and appendixes. 2020.
Geldof L, Pozo OJ, Lootens L, Morthier W, Van Eenoo P, Deventer K. In vitro metabolism study of a black market product containing SARM LGD-4033. Drug Test Anal. 2017;9(2):168-178. https://doi.org/10.1002/dta.1930
Hansson A, Knych H, Stanley S, Thevis M, Bondesson U, Hedeland M. Investigation of the selective androgen receptor modulators S1, S4 and S22 and their metabolites in equine plasma using high-resolution mass spectrometry. Rapid Commun Mass Spectrom. 2016;30(7):833-842. https://doi.org/10.1002/rcm.7512
WADA. Prohibited list. 2020.
FEI. Prohibited list. https://inside.fei.org/fei/cleansport/ad-h/prohibited-list
Thevis M, Beuck S, Thomas A, et al. Doping control analysis of emerging drugs in human plasma - identification of GW501516, S-107, JTV-519, and S-40503. Rapid Commun Mass Spectrom. 2009;23(8):1139-1146. https://doi.org/10.1002/rcm.3987
Thevis M, Möller I, Thomas A, et al. Characterization of two major urinary metabolites of the PPARdelta-agonist GW1516 and implementation of the drug in routine doping controls. Anal Bioanal Chem. 2010;396(7):2479-2491. https://doi.org/10.1007/s00216-009-3283-x
Thevis M, Möller I, Beuck S, Schänzer W. Synthesis, mass spectrometric characterization, and analysis of the PPARδ agonist GW1516 and its major human metabolites: targets in sports drug testing. Methods Mol Biol. 2013;952:301-312.
Sobolevsky T, Dikunets M, Sukhanova I, Virus E, Rodchenkov G. Detection of PPARδ agonists GW1516 and GW0742 and their metabolites in human urine. Drug Test Anal. 2012;4(10):754-760. https://doi.org/10.1002/dta.1413
Kintz P, Ameline A, Gheddar L, Raul J-S. Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS. Drug Test Anal. 2020;12(7):980-986. https://doi.org/10.1002/dta.2802
Gray B, Viljanto M, Menzies E, Vanhaecke L. Detection of prohibited substances in equine hair by ultra-high performance liquid chromatography-triple quadrupole mass spectrometry-application to doping control samples. Drug Test Anal. 2018;10(7):1050-1060. https://doi.org/10.1002/dta.2367
Ishii H, Leung GN-W, Yamashita S, et al. Doping control analysis of GW1516 in equine plasma using liquid chromatography/electrospray ionization Q-Exactive high-resolution mass spectrometry. Rapid Commun Mass Spectrom. 2020;34:e8920. https://doi.org/10.1002/rcm.8920
Delcourt V, Barnabé A, Loup B, et al. MetIDfyR: an open-source R package to decipher small-molecule drug metabolism through high-resolution mass spectrometry. Anal Chem. 2020;92(19):13155-13162. https://doi.org/10.1021/acs.analchem.0c02281
Adams KJ, Pratt B, Bose N, et al. Skyline for small molecules: a unifying software package for quantitative metabolomics. J Proteome Res. 2020;19(4):1447-1458. https://doi.org/10.1021/acs.jproteome.9b00640
MacLean B, Tomazela DM, Shulman N, et al. Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics. 2010;26(7):966-968. https://doi.org/10.1093/bioinformatics/btq054
AORC. AORC guidelines for the minimum criteria for identification by chromatography and mass spectrometry. 2016.
DrugBank. https://www.drugbank.ca/drugs/DB05416. n.d.
Moulard Y, Bailly-Chouriberry L, Boyer S, Garcia P, Popot M-A, Bonnaire Y. Use of benchtop exactive high resolution and high mass accuracy orbitrap mass spectrometer for screening in horse doping control. Anal Chim Acta. 2011;700(1-2):126-136. https://doi.org/10.1016/j.aca.2011.01.006